Key Positives From The Results
New consolidation of Kanarabo (+JPY 645M) and clinic-related entities (+JPY 178M) drove top-line growth, lifting consolidated revenue to JPY 1,317M, up +69.3% YoY. Operating loss narrowed from a JPY 161M loss to a JPY 141M loss, while adjusted EBITDA improved from a JPY 113M loss to a JPY 63M loss, confirming the trajectory toward profitability. The company has entered a phase where its ability to scale the business portfolio and replicate brand-building success will be put to the test.
- Fujiko posted 1Q revenue of JPY 517M; hero product "Pore Odamari! Cream" achieved an 87.6% repeat purchase rate, establishing itself as a staple item
- b idol generated 1Q revenue of JPY 141M (+JPY 23M QoQ); following a double Best Cosmetics award win, award-winning product sales surged ~230%
- WinC slashed ad spend from JPY 194M to JPY 31M, improving business-level profit by +JPY 54M (from a JPY 109M loss to a JPY 55M loss)
- Matsumura Shoten delivered a gross margin of 47.3%, exceeding the 41.8% plan, with mall-based sales driving the outperformance
- bialne launched a loyalty program for subscription members, resulting in ~2.4x new sign-ups and ~2.6x reactivations of dormant subscribers
Key Concerns From The Results
Core brand MiiS posted revenue of JPY 108M (−33.3% YoY), underperforming its plan and serving as the single largest drag on operating profit. Disclosure of material events, etc. related to the going concern assumption continues to be included. Operating cash flow has been negative for two consecutive fiscal years, and cash on hand of JPY 521M warrants close monitoring from a liquidity standpoint.
- MiiS 1Q revenue came in at JPY 108M (−33.3% YoY), primarily due to timing slippage on a large wholesale deal and deteriorating promotional economics on e-commerce marketplaces
- Gross margin declined to 50.6% (−2.4pp YoY), reflecting a shift in revenue mix toward lower-margin businesses and COGS timing effects at MiiS
- Net loss widened to JPY 177M, driven by a swing from a JPY 52M tax refund in the prior year to JPY 26M in tax charges this period
- Equity ratio fell to 16.5% (vs. 19.2% at prior FYE), marking the fourth consecutive annual decline; goodwill of JPY 2,289M represents 42.9% of total assets
- Interest expense reached JPY 19M (+94.0% YoY), reflecting higher debt levels from M&A financing
Focus Areas / Items To Monitor Going Forward
- Sales trajectory of MiiS's new product "LIFT BRUSH" (JPY 39,800 incl. tax) following its general launch, and distribution expansion into new channels such as Qoo10 and Loft. Whether this high-price-point beauty device can penetrate the existing oral care user base will be key to a 2Q recovery
- Whether Kanarabo's Fujiko and b idol brands can sustain above-plan performance during the 2H mega-sale events on Amazon and Rakuten. Impact on gross margin from the rollout to ~3,000 drugstore locations via the wholesale channel
- Timeline for operating cash flow turning positive and potential need for additional fundraising. Achieving full-year operating income of JPY 50M requires an incremental JPY 191M contribution from 2Q onward — the trajectory of MiiS recovery and company-wide cost discipline will determine whether guidance is achievable
- Specific monetary scale of the MiiS large wholesale deal timing slippage and confidence in 2Q shipment
- Early sell-through data and inventory levels for MiiS LIFT BRUSH following its general launch
- Plans to revise profitability management criteria for e-commerce marketplace promotions (coupon campaigns)
- Payback plan and PMI progress for goodwill associated with the Kanarabo acquisition (estimated ~JPY 1.5B)
- Expected impact on Fujiko's gross margin from the rollout to 3,000 drugstore locations
- KPI targets from 2Q onward for bialne's 4,749 subscription members and 93.0% retention rate
- Scale of trading card procurement and timeline for revenue contribution from Oripa Shop (launched July 31)
- Annual revenue target for the whomee rebrand
- Breakdown and room for reduction in holding company overhead of JPY 238M (full-year plan)
- Expected timeline for operating cash flow break-even and likelihood of additional equity financing
Key Financial Highlights
| Item | Value | YoY |
|---|---|---|
| Revenue | JPY 1,317M | +69.3% |
| Cost of Goods Sold | JPY 651M | +78.1% |
| Gross Profit | JPY 666M | +61.5% |
| Gross Profit Margin | 50.6% | −2.4pp |
| SG&A | JPY 807M | +40.7% |
| Operating Income | −JPY 141M | Loss narrowed (vs. −JPY 161M in prior year) |
| Recurring Profit | −JPY 151M | Loss narrowed (vs. −JPY 167M in prior year) |
| Net Income Attributable to Owners of Parent Company (Quarterly) | −JPY 177M | Loss widened (vs. −JPY 115M in prior year) |
| EPS | −JPY 51.84 | Loss widened (vs. −JPY 38.79 in prior year) |
| Adjusted EBITDA | −JPY 63M | Loss narrowed (vs. −JPY 113M in prior year) |
| Adjusted Quarterly Net Income | −JPY 61M | Loss narrowed (vs. −JPY 85M in prior year) |
| Depreciation | JPY 16M | +111.9% |
| Goodwill Amortization | JPY 54M | +192.5% |
The widening of the net loss was primarily attributable to the reversal of a JPY 52M tax refund booked in the prior-year period and the recognition of JPY 26M in income taxes in the current period. At the recurring profit level, the company posted a JPY 16M improvement.
Performance By Business Segment
As the company operates under a single reportable segment (Brand Produce Business), no segment-level financial disclosure is provided in the statutory filings. However, the earnings presentation materials break out revenue across three business domains. The Proprietary Brands domain expanded +264.6% driven by new consolidation of Kanarabo and clinic-related entities, accounting for 77.7% of total revenue. The Planning & Contract Manufacturing domain declined −30.6% due to reduced shelf space at variety stores. The Other New Businesses domain contracted −46.3% following the divestiture of Rice Curry's lifestyle business.
Segment Performance Table
| Segment | Revenue | YoY | Operating Income | YoY | Margin |
|---|---|---|---|---|---|
| Brand Produce Business (Consolidated) | JPY 1,317M | +69.3% | −JPY 141M | Loss narrowed | - |
| Business Domain | Revenue | YoY |
|---|---|---|
| Proprietary Brands | JPY 1,024M | +264.6% |
| Planning & Contract Manufacturing | JPY 117M | −30.6% |
| Other New Businesses | JPY 176M | −46.3% |
- Fujiko (Kanarabo / Beauty & Cosmetics): 1Q revenue of JPY 517M; in addition to the new consolidation effect, "Pore Odamari! Cream" sold ~30,000 units within two weeks of launch, and five items ranked in Best Cosmetics lists, expanding brand awareness
- b idol (Kanarabo / Beauty & Cosmetics): 1Q revenue of JPY 141M (+JPY 23M QoQ); "Magical Eyebrow Powder" won the #1 eyebrow product award from both VoCE and Biteki, driving ~230% sales growth post-award
- Matsumura Shoten (Planning & Contract Manufacturing / Fashion Accessories): Revenue per client recovered to JPY 5.6M (+3.7% YoY); a Gloomy Bear collaboration product reached #1 on Rakuten's daily ranking, driven by social media virality
- MiiS (WinC / Oral Care): 1Q revenue of JPY 108M (−33.3% YoY); a confluence of timing slippage on a large wholesale deal, deteriorating e-commerce marketplace promotional economics, and underperformance versus Qoo10 Mega Sale volume targets
- Rice Curry Plus (Other New Businesses / SNS Marketing Support): 1Q revenue of JPY 176M (−46.3% YoY); scale contracted following the divestiture of the lifestyle business. Revenue per employee of JPY 8.4M is trending upward
Progress Versus Full-Year Guidance
1Q revenue progress of 19.9% is broadly in line with the past two years (FY3/25: 21.5%, FY3/26: 18.8%). However, with an operating loss of JPY 141M booked in 1Q, achieving the full-year break-even target (JPY 50M operating income) requires an incremental JPY 191M from 2Q onward. The company has maintained its full-year guidance, citing above-plan performance at Kanarabo, Matsumura Shoten, and HaD, a MiiS recovery scenario (LIFT BRUSH launch and channel expansion), and corporate cost containment. While the earnings profile is structurally 2H-weighted, the probability of achievement will need to be reassessed based on 2Q results.
| Item | Value (1Q Cumulative) | Full-Year Forecast | Progress Rate |
|---|---|---|---|
| Revenue | JPY 1,317M | JPY 6,602M | 19.9% |
| Operating Income | −JPY 141M | JPY 50M | - |
| Adjusted EBITDA | −JPY 63M | JPY 324M | - |
| Adjusted Net Income | −JPY 61M | JPY 128M | - |
- The earnings profile is structurally 2H-weighted. Major e-commerce marketplace sales events (Amazon Prime Day, Black Friday, etc.) are concentrated in 2H, driving higher Proprietary Brands revenue
- Matsumura Shoten's Planning & Contract Manufacturing business sees peak demand in the January–March period tied to the back-to-school season
Changes To Guidance
No changes from the full-year guidance announced on May 14, 2026. Management views the MiiS 1Q shortfall as driven by temporary factors and expects to absorb the miss through above-plan performance at Kanarabo and Matsumura Shoten, along with new product launches and channel expansion from 2Q onward.
Commentary On Shareholder Returns
The annual dividend forecast for FY3/27 remains JPY 0.00 (unchanged from JPY 0.00 in the prior year). No share buybacks or changes to the shareholder return policy have been announced.
Financial Position
The equity ratio has declined for four consecutive years to 16.5%, reflecting goodwill accumulation from accelerating M&A activity and cumulative losses. Operating cash flow has been negative for two consecutive fiscal years, and material events, etc. related to the going concern assumption have been disclosed. However, the company has assessed that no material uncertainty exists given that funding arrangements are in place.
- Key Figures
- Leverage Metrics
| Item | Value | Additional Information |
|---|---|---|
| Total Assets | JPY 5,337M | −5.5% vs. prior FYE |
| └ Total Current Assets | JPY 2,370M | −9.5% vs. prior FYE |
| └ Total Non-Current Assets | JPY 2,951M | −2.0% vs. prior FYE |
| Cash and Deposits | JPY 521M | −24.3% vs. prior FYE |
| Goodwill | JPY 2,289M | 42.9% of total assets |
| Total Interest-Bearing Debt | JPY 3,342M | −JPY 199M from prior FYE (JPY 3,541M) |
| └ Short-Term Borrowings | JPY 750M | −8.5% vs. prior FYE |
| └ Long-Term Borrowings (incl. current portion) | JPY 2,372M | −5.2% vs. prior FYE |
| └ Bonds (incl. current portion) | JPY 210M | Unchanged from prior FYE |
| Shareholders' Equity | JPY 882M | −18.7% vs. prior FYE |
| EBITDA | −JPY 69M | OI −141 + Depreciation 16 + Goodwill amortization 54; our estimate |
News Released Alongside The Earnings Announcement
None
Major Announcements During The Quarter
- 2026/06/03Announced the launch of four items as the first phase of the whomee rebrand, with priority distribution at 70 PLAZA stores nationwide and on Qoo10 Igari Shinobu-produced "whomee" rebrand Phase 1: A new approach starting from base makeup — four items launching sequentially from August 21, 2026
- 2026/06/17Consolidated subsidiary WinC announced its entry into the online gacha market with "Oripa Shop," planning to acquire JPY 50–100M in trading cards Notice Regarding Trading Card Investment and Entry into the Oripa Business Based on Growth-Return Treasury Strategy
- 2026/07/10Announced the confirmed rollout of Fujiko's "Pore Odamari! Cream" to ~3,000 major drugstore locations Fujiko "Pore Odamari! Cream" confirmed for rollout to ~3,000 major drugstore locations — trial size (1.5g) bundle to be available sequentially from around September
- 2026/07/22Announced the general launch of MiiS LIFT BRUSH on August 10; Makuake crowdfunding pledges exceeded ~JPY 14.5M MiiS LIFT BRUSH — an electric toothbrush designed for facial lift-up*1 through intraoral facial muscle stimulation, which surpassed JPY 14.5M in Makuake pledges — to go on general sale from Monday, August 10, 2026!
- 2026/08/05MiiS's flagship supplement "mm flora*" series surpassed cumulative sales of 800,000 units; now available at PLAZA stores nationwide Cumulative series sales exceed 800,000 units!1 Oral beauty brand "MiiS" — protective supplement "mm flora" available at PLAZA stores nationwide from Saturday, August 8!
Large-Shareholding Filings / Material Proposals Over The Past Year
- ULTIMATE CLASSIC INVESTMENT LLC: 0% → 10.94% (reporting obligation triggered 2026/03/05; filed 2026/04/03, corrected 04/06) — Pure investment. Supports medium- to long-term corporate value enhancement while respecting the current management's policies
- Ryo Okubo (Representative Director): 36.84% → 37.46% (reporting obligation triggered 2025/08/07) — Pure investment. 220,000 shares pledged as collateral under a loan agreement with Tokai Tokyo Securities
ENVALITH, INC. ("ENVALITH") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.
- Purpose and Disclaimer Regarding Investment Decisions
This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and ENVALITH and subject company shall not be involved in any such investment decisions.
- Information Sources, Accuracy, and Disclaimer of Warranty
This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. ENVALITH has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by ENVALITH using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, ENVALITH and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. ENVALITH and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.
- Limitation of Liability
ENVALITH and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.
- Potential Conflicts of Interest
ENVALITH may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.
- No Obligation to Change or Update Content
The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that ENVALITH is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.
- Governing Language
This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.
- Copyright
All rights (including copyrights) relating to this report belong to ENVALITH. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of ENVALITH is strictly prohibited.
- Use for Other Investment Products
Except where ENVALITH has provided prior written approval, the use of this report and the trademarks or trade names of ENVALITH or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.

